Iran War Spokane Wildfires World Politics Entertainment HealthWatch MoneyWatch Crime Space Sports Brand Studio The Free Press Local News Atlanta Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas Live CBS News 24/7 Baltimore Bay Area Boston Chicago Colorado Detroit Los Angeles Miami Minnesota New York Philadelphia Pittsburgh Sacramento Texas 48 Hours 60 Minutes Shows 48 Hours 60 Minutes CBS Evening News CBS Mornings CBS Morning News CBS Reports CBS Saturday Morning The Daily Report The Dish Face the Nation Sunday Morning The Takeout Things That Matter The Uplift CBS News Investigates CBS News Confirmed Podcasts Newsletters Download Our App CBS News Team Executive Team Brand Studio Paramount+ Join Our Talent Community RSS Feeds Boston | News Weather Sports Video WBZ Features All News Health I-Team Politics Education Business Consumer Entertainment NEXT Weather Forecast Radar & Maps School Closings School Visits Earth Matters Share Photos and Videos Join Weather Watchers All Sports CBS Sports HQ Patriots Red Sox Celtics Bruins Revolution Odds New England Living Question Everything It Happens Here Keller @ Large Wednesday's Child Climate Watch Change Makers Contact Us TV Schedule Meet Our Team Station Info Contests Jobs & Internships Download Our App Obituaries Watch CBS News Doctor says anyone using GLP-1 should focus on muscle-preserving strategies Millions of people are using GLP-1 medications to lose weight, but doctors say shedding pounds is just one part of the equation

Patrick Carroll, Chief Medical Officer of Hims & Hers
Lilly's other two weight loss medications, Zepbound and Mounjaro, are taken as weekly injections, like Novo Nordisk's Ozempic.
& Kletsas, D
DAO (Diamine oxidase), a rate limiting enzyme converts putrescine into gamma amino butyraldehyde, further aminoaldehyde dehydrogenase (AMADH) converts gamma-amino butyraldehyde into GABA
We know there are people who are interested in addressing their weight but have been waiting on the sidelines for a medicine that was right for them, Ed Cinca, senior vice president of marketing & patient solutions at Novo Nordisk said in the press release